MDGL
Madrigal Pharmaceuticals Inc.
$520.77
+$3.51(+0.68%)
50
Overall
40
Value
66
Tech
44
Quality
Market Cap
$11.80B
Volume
80.62K
52W Range
$265.00 - $615.00
Target Price
$672.56
Company Overview
| Mkt Cap | $11.80B | Price | $520.77 |
| Volume | 80.62K | Change | +0.68% |
| P/E Ratio | -40.9 | Open | $516.48 |
| Revenue | $958.4M | Prev Close | $517.26 |
| Net Income | $-288.3M | 52W Range | $265.00 - $615.00 |
| Div Yield | N/A | Target | $672.56 |
| Overall | 50 | Value | 40 |
| Quality | 44 | Technical | 66 |
No chart data available
About Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest News
Madrigal’s Rezdiffra Drives Blockbuster Growth Amid Costs
TipRanks Auto-Generated Newsdesk•7 days ago
Truist Financial Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)
TipRanks Auto-Generated Intelligence Newsdesk•13 days ago
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays
TipRanks Auto-Generated Intelligence Newsdesk•18 days ago
Madrigal Earnings Call: Rezdiffra Boom, Profits Delayed
TipRanks Auto-Generated Newsdesk•20 days ago
Madrigal Earnings Call: Rezdiffra Boom, Profits Delayed
TipRanks Auto-Generated Newsdesk•20 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDGL | $520.77 | +0.7% | 80.62K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Madrigal Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW